Cancer cell expression of urokinase-type plasminogen activator receptor mRNA in squamous cell carcinomas of the skin

Journal of Investigative Dermatology

Volumn 116, Issue 3, 2001, Pages 353-358

  Rømer, John ^a,b   Pyke, Charles ^a,b   Lund, Leif R ^a   Ralfkiær, Elisabeth ^a,c   Danø, Keld ^a  

^a FINSEN LABORATORY   (Denmark)

^b NOVO NORDISK A S   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Extracellular proteolysis; Plasminogen; Skin carcinoma; uPA uPAR Wound healing

Indexed keywords

COMPLEMENTARY RNA; MESSENGER RNA; UROKINASE RECEPTOR;

ARTICLE; BASAL CELL CARCINOMA; CANCER CELL; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA PROBE; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA;

EID: 0035092563     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.2001.01241.x     Document Type: Article

References (51)

1. Saarialho-Kere UK: Human collagenase-3 is expressed in malignant squamous epithelium of the skin
2. Expression of stromelysin 3 in keratoacanthoma and squamous cell carcinoma
3. The urokinase receptor
4. Proteolysis, cell adhesion, chemotaxis, and invasiveness are regulated by the u-PA-u-PAR-PAI-1 system
5. Urokinase-type plasminogen activator: Proenzyme receptor and inhibitors
6. Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency
7. Reduced metastasis of polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice
8. Prevention of metastasis by inhibition of the urokinase receptor
9. The urokinase receptor: Protein structure and role in plasminogen activation and cancer invasion
10. Cancer invasion and tissue remodeling - Cooperation of protease systems and cell types
11. Tumors. Wounds that do not heal
12. Plasminogen activation by receptor-bound urokinase: A kinetic study with both cell-associated and isolated receptor
13. Gene expression and function of the cellular receptor for u-PA (u-PAR)
14. Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein (a) mice
15. Urokinase- and tissue-type plasminogen activators in keratinocytes during wound reepithelialization in vivo
16. Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans
17. The intact urokinase receptor is required for efficient vitronectin binding: Receptor cleavage prevents ligand interaction
18. Cancer invasion and tissue remodeling: Common themes in proteolytic matrix degradation
19. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semiquantitative PCR-based assay
20. The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy
21. Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse
22. Two distinct phases of apoptosis in mammary gland involution: Proteinase-independent and -dependent pathways
23. Functional overlap between two classes of matrix degrading proteases in wound healing
24. Lactational competence and involution of the mouse mammary gland require plasminogen
25. Matrix metalloproteinases (MMPs) and their physiological inhibitors (TIMPs) are differentially expressed during excisional skin wound repair
26. Low levels of urokinase plasminogen activator components in basal cell carcinoma of the skin
27. Biology and biochemistry of proteinases in tumor invasion
28. Urokinase plasminogen activator is immunocytochemically detectable in squamous cell but not basal cell carcinomas
29. Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer
30. Proteolytic activation of the precursor of membrane type 1 matrix metalloproteinase by human plasmin. A possible cell surface activator
31. In vivo paracrine interaction between urokinase and its receptor - Effect on tumour cell invasion
32. Detection of mRNAs encoding collagenase I and stromelysin- 2 in carcinomas of the head and neck by in situ hybridization
33. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas
34. Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization
35. Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma
36. Immunohistochemical detection of the receptor for urokinase plasminogen activator in human colon cancer
37. Differential expression of urokinase-type plasminogen activator and its type-1 inhibitor during healing of mouse skin wounds
38. The receptor for urokinase-type plasminogen activator is expressed by keratinocytes at the leading edge during re-epithelialization of mouse skin wounds
39. Impaired wound healing in mice with a disrupted plasminogen gene
40. Cell-matrix interactions modulate interstitial collagenase expression by human keratinocytes actively involved in wound healing
41. Distinct populations of basal keratinocytes express stromelysin-1 and stromelysin-2 in chronic wounds
42. Expression of matrix metalloproteinase-2 and -9 during early human wound healing
43. Differential protease expression by cutaneous squamous and basal cell carcinomas
44. Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: Cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals
45. Expression of plasminogen activators in basal cell carcinoma
46. Expression of matrix metalloproteinase-1, -2 and -3 in squamous cell carcinoma and actinic keratosis
47. The urokinase receptor
48. Identification of the urokinase receptor as an adhesion receptor for vitronectin
49. Regulation of integrin function by the urokinase receptor
50. Endogeneous activation of latent collagenase by rheumatoid synovial cells
51. Breast-cancer-associated stromelysin-3 gene is expressed in basal cell carcinoma and during cutaneous wound healing